US20220259209A1 details a process for manufacturing abrocitinib, an orally administered Janus kinase 1 (JAK1) selective inhibitor. The patent describes a method for producing crystalline abrocitinib, which is an important intermediate in the synthesis of the active pharmaceutical ingredient [1].
How is abrocitinib manufactured?
The patent US20220259209A1 outlines a specific process for obtaining crystalline abrocitinib. This process involves treating abrocitinib with a solvent or solvent mixture. The resulting crystalline form is then isolated, typically by filtration, and dried [1]. This controlled crystallization is crucial for obtaining a pure and stable intermediate necessary for drug formulation.
What is abrocitinib used for?
Abrocitinib is approved for the treatment of adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy. It works by selectively inhibiting JAK1, which plays a role in the immune response and inflammation associated with atopic dermatitis [2].
When did abrocitinib receive FDA approval?
Abrocitinib, marketed as Cibinqo, received FDA approval in January 2022 for the treatment of moderate-to-severe atopic dermatitis in adults [3].
Are there patents protecting abrocitinib?
Yes, abrocitinib is protected by several patents. DrugPatentWatch.com tracks these patents, including those related to its composition of matter and manufacturing processes [4]. The patent US20220259209A1 is one such example focused on a specific manufacturing step.
What companies are involved with abrocitinib?
Pfizer Inc. is the primary company associated with the development and marketing of abrocitinib [2, 3].
How does abrocitinib compare to other atopic dermatitis treatments?
Abrocitinib is a JAK inhibitor, a class of drugs that target specific inflammatory pathways. Other treatments for atopic dermatitis include topical corticosteroids, calcineurin inhibitors, and other systemic agents. The choice of treatment depends on disease severity, patient history, and response to therapy [2].
What are the potential side effects of abrocitinib?
Common side effects associated with abrocitinib can include upper respiratory tract infections, acne, and increased levels of blood creatine phosphokinase [2]. Serious risks may include major adverse cardiovascular events, thrombosis, secondary malignancies, and serious infections [2].
What is the general timeline for drug patent expiry?
For small molecule drugs like abrocitinib, patents typically provide market exclusivity for a period of 20 years from the filing date. However, various extensions and Hatch-Waxman Act provisions can adjust this timeline. The specific expiry dates for abrocitinib patents can be researched through resources like DrugPatentWatch.com [4].
Can generic versions of abrocitinib be developed before patent expiry?
Generally, generic versions, or biosimilars in the case of biologics, cannot be marketed until the relevant patents expire or are successfully challenged. The development of abrocitinib generics would be contingent on the expiration or invalidation of its patent protections [4].
Sources:
1. US20220259209A1 (Google Patents)
2. Cibinqo (abrocitinib) prescribing information. Pfizer Inc.
3. "FDA approves Cibinqo (abrocitinib) for the treatment of adults with moderate-to-severe atopic dermatitis." U.S. Food and Drug Administration. January 14, 2022.
4. DrugPatentWatch.com